|
KMID : 0043320070300060723
|
|
Archives of Pharmacal Research
2007 Volume.30 No. 6 p.723 ~ p.732
|
|
|
β-Galactoside Prodrugs of Doxorubicin for Application in Antibody Directed Enzyme ProdrugTherapy/Prodrug MonoTherapy
|
|
Devalapally HariKrishna
Navath Raghavendra Swamy
Yenamandra Venkateshwarlu
Akkinepally RaghuRam Rao
Devarakonda Rama Krishna
|
|
|
Abstract
|
|
|
|
Anthracycline antibiotics, particularly doxorubicin and daunorubicin, have been used extensively in the treatment of human malignancies. However cardiotoxicity and multidrug resistance are significant problems that limit the clinical efficacy of such agents. Rational design to avoid these side effects includes strategies such as drug targeting and prodrug synthesis. Described here are the synthesis and preliminary biological evaluation of the enzymatically activated two new prodrugs (6 & 11) of doxorubicin. These prodrugs were designed as potential candidates for selective chemotherapy in ADEPT or PMT strategies. They are constituted of a galactose moiety, a spacer and the cytotoxic drug and they differ by the type of spacer. The prodrugs were stable in a buffer, and the in vitro studies showed good detoxification and hydrolysis kinetics. As prodrug 11 was readily hydrolyzed, this could be a valuable candidate for further development.
|
|
|
KEYWORD
|
|
|
Prodrugs, Doxorubicin, Stability, Hydrolysis, Release kinetics, In vitro cytotoxicity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|